South Africa’s three major health regulatory bodies — the South African Health Products Regulatory Authority (SAHPRA), the Health Professions Council of South Africa (HPCSA), and the South African Pharmacy Council (SAPC) — issued a joint warning on 8 July 2026 regarding recalled iDexis GLP-1 products.
The recall, classified as Class I, Type A — the most serious category reserved for products posing a severe risk to public health — followed a joint inspection of iDexis’s Pretoria facility. Inspectors found the company was manufacturing and supplying unregistered GLP-1 medicines beyond the scope permitted under South Africa’s compounding framework. SAHPRA ordered the products off the market and seized stock.
Healthcare professionals who continue to prescribe, dispense, or hold stock of the recalled products face disciplinary action under the Medicines and Related Substances Act. iDexis has rejected the findings, stating it legally compounded the medicines using quality-tested active pharmaceutical ingredients. The recall has become the subject of legal proceedings.
Sources
- Mail & Guardian, 9 July 2026
- Reuters, 9 July 2026
- Joburg Etc, 9 July 2026 — SAHPRA/HPCSA/SAPC joint statement